drugset / Trial / NCT06015035
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The study focused on patients with T2-4NxM0 resectable esophageal carcinoma. Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200 mg) and chemotherapyfor three cycles. Surgical treatment was performed 4-6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) rate and safety.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2022-04-01
- Completion
- 2022-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Nedaplatin | Small molecule | 80 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 130 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |
Indications
No indication recorded.